Eli Lilly's late-stage pipeline features such products as retatrutide, a potential novel weight loss treatment. Eli Lilly broke new ground with Zepbound. It's a dual GLP-1/GIP agonist, meaning it ...
This is on top of NVO's promising pipeline, amycretin, offering accelerated weight loss results compared to CagriSema and LLY's Zepbound/ Retatrutide. Even so, we had believed that FY2025 was ...
It also reported preliminary data with an oral triple agonist called retatrutide – targeting GLP-1, GIP, and glucagon – that is also being advanced quickly into phase 3. Shares in Pfizer fell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback